The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
REGULATORY
AstraZeneca’s COVID Antibody, Daiichi’s TROP2 ADC, and More Up for Review on Dec. 6
A key health ministry advisory panel will discuss whether to recommend approval for a batch of new medicines on December 6, including AstraZeneca’s sipavibart, a long-acting antibody for the pre-exposure prophylaxis of COVID-19 in immunocompromised patients. A total of nine…
To read the full story
Related Article
- Daiichi Sankyo’s TROP2 ADC, AZ’s COVID Antibody, Mpox Med in Line for Japan Approval
December 9, 2024
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- Janssen Files Bispecific Teclistamab for MM in Japan
May 23, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
- Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Sanofi Files High-Dose Quadrivalent Flu Vaccine in Japan
December 20, 2023
REGULATORY
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
April 28, 2025
- MHLW/PMDA, FDA Philippines to Boost Regulatory Cooperation
April 28, 2025
- LDP Members Raise No Call for Tax Cuts, Fret Inflationary Impact on Medical Facilities: Fiscal Reform HQ
April 25, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…